Vialwise
EN

DSIP

DSIP (delta sleep-inducing peptide, also called emideltide) is a small peptide first found in rabbits and named for an apparent effect on deep sleep. Its natural role is still unclear; a 2006 review noted that no gene or receptor for it had been found. Human sleep studies from the 1980s and 1990s gave mixed results.

Not approved · research onlyWADA Not named; falls under S0 (non-approved substances)Checked October 2026
Open the DSIP calculatorSources

Approval status

Not approved by the FDA or EMA, and not part of any FDA-approved drug. In a 2026 review for a US advisory committee, FDA staff found insufficient evidence of benefit and advised against letting pharmacies compound it. In July 2026 the committee also voted against it, 7–6, according to news reports.31314

What it’s used or studied for

  • Human studies

    Chronic insomnia, in small intravenous trials. Early studies reported better sleep; later placebo-controlled trials found little or no benefit.3456

  • Human studies

    Alcohol and opioid withdrawal, in uncontrolled studies that reported fewer withdrawal symptoms.378

  • Human studies

    Chronic pain episodes, including migraine, in a pilot study of seven people.9

  • Human studies

    Narcolepsy, in a single case report.310

  • Animal & lab only

    Seizures and brain injury from reduced blood flow, in rats.1112

Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.

Side effects

Common

  • Headache
  • Sweating
  • Nausea
  • Dizziness (vertigo)

Serious or rare

  • Low blood pressure, in a withdrawal study

These effects come from small studies of intravenous DSIP, mostly in people going through alcohol or opioid withdrawal, whose own symptoms overlap. FDA found no human safety data for injection under the skin.37

Cautions

  • FDA notes DSIP acts partly through the body's opioid system and that its potential for addiction has not been studied.3
  • FDA raised concerns about impurities and immune reactions, which may be greater when it is injected under the skin.3

Sources

  1. PubChem: Delta sleep-inducing peptide (CID 68816)
  2. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006 (review)
  3. FDA briefing document: Emideltide (DSIP)-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 2026
  4. Schneider-Helmert D, Schoenenberger GA. Synthetic DSIP and disturbed human sleep. Experientia 1981
  5. Bes F et al. Effects of DSIP on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology 1992
  6. Monti JM et al. DSIP efficacy in improving sleep in chronic insomniacs. Int J Clin Pharmacol Res 1987
  7. Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol 1984
  8. Backmund M et al. Opioid detoxification with DSIP: results of an open clinical trial. J Clin Psychopharmacol 1998
  9. Larbig W et al. DSIP in patients with chronic, pronounced pain episodes: a pilot study. Eur Neurol 1984
  10. Schneider-Helmert D. Effects of DSIP on narcolepsy. Eur Neurol 1984 (case report)
  11. Stanojlović OP et al. Antiepileptic activity of DSIP and its analogue in rats. Seizure 2005
  12. Shandra AA et al. Effects of DSIP in cerebral ischemia in rats. Neurosci Behav Physiol 1998
  13. STAT news: FDA advisory panel narrowly rejects compounding of one peptide, backs two others (July 24, 2026)
  14. World Anti-Doping Agency: 2026 Prohibited List

Spotted a mistake on this page? Report it. The email opens with the peptide and vial already filled in.